Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christopher Paul Crum, M.D.

Co-Author

This page shows the publications co-authored by Christopher Crum and Neil Horowitz.
Connection Strength

1.541
  1. Molecular catastrophe, the peritoneal cavity and ovarian cancer prevention. J Pathol. 2022 Mar 02.
    View in: PubMed
    Score: 0.247
  2. The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecol Oncol. 2019 02; 152(2):426-433.
    View in: PubMed
    Score: 0.198
  3. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. J Pathol. 2018 11; 246(3):344-351.
    View in: PubMed
    Score: 0.195
  4. Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. Gynecol Oncol. 2017 07; 146(1):69-73.
    View in: PubMed
    Score: 0.177
  5. Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Mod Pathol. 2017 03; 30(3):448-458.
    View in: PubMed
    Score: 0.171
  6. Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel). 2021 Jun 28; 13(13).
    View in: PubMed
    Score: 0.059
  7. Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
    View in: PubMed
    Score: 0.058
  8. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
    View in: PubMed
    Score: 0.056
  9. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
    View in: PubMed
    Score: 0.051
  10. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
    View in: PubMed
    Score: 0.049
  11. Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2017 Mar; 36(2):115-127.
    View in: PubMed
    Score: 0.044
  12. Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecol Oncol. 2016 08; 142(2):293-8.
    View in: PubMed
    Score: 0.042
  13. Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prev Res (Phila). 2016 Sep; 9(9):713-20.
    View in: PubMed
    Score: 0.041
  14. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016 Apr; 2(4):518-22.
    View in: PubMed
    Score: 0.041
  15. Epithelioid trophoblastic tumor: A single institution case series at the New England Trophoblastic Disease Center. Gynecol Oncol. 2015 Jun; 137(3):456-61.
    View in: PubMed
    Score: 0.038
  16. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol. 2015 Mar; 39(3):287-93.
    View in: PubMed
    Score: 0.038
  17. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014 Feb; 132(2):280-6.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.